留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

移植后糖尿病危险因素研究进展

董骏峰, 薛强, 滕飞, 等. 移植后糖尿病危险因素研究进展[J]. 器官移植, 2024, 15(1): 145-150. doi: 10.3969/j.issn.1674-7445.2023154
引用本文: 董骏峰, 薛强, 滕飞, 等. 移植后糖尿病危险因素研究进展[J]. 器官移植, 2024, 15(1): 145-150. doi: 10.3969/j.issn.1674-7445.2023154
Dong Junfeng, Xue Qiang, Teng Fei, et al. Research progress in risk factors of post-transplantation diabetes mellitus[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 145-150. doi: 10.3969/j.issn.1674-7445.2023154
Citation: Dong Junfeng, Xue Qiang, Teng Fei, et al. Research progress in risk factors of post-transplantation diabetes mellitus[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 145-150. doi: 10.3969/j.issn.1674-7445.2023154

移植后糖尿病危险因素研究进展

doi: 10.3969/j.issn.1674-7445.2023154
基金项目: 国家自然科学基金面上项目(82070798);上海市科学技术委员会生物医药创新项目(21S11905200);上海申康医院发展中心新兴前沿技术联合攻关项目(SHDC12021116);上海申康医院发展中心研究型医师创新转化能力培训项目(SHDC2022CRD030);上海长征医院转化医学孵育基金;上海长征医院科普人才扶持计划(CZQNKP-TYYX-QZ-2022-05)
详细信息
    作者简介:
    通讯作者:

    殷浩(ORCID 0000-0001-5674-8681),主任医师,全军器官移植研究所所长,国家重点学科/国家临床重点专科学科带头人,研究方向为肝胆胰腺外科及器官移植,Email:roytina0241032@hotmail.com

  • 中图分类号: R617, R587.1

Research progress in risk factors of post-transplantation diabetes mellitus

More Information
  • 摘要: 实体器官移植极大地延长了终末期疾病患者的生存时间,但器官移植受者术后需要长期服用免疫抑制药,会导致移植后糖尿病(PTDM)的发生风险增加,从而使感染、心血管疾病和死亡的风险升高。近年来,随着PTDM诊断标准的不断完善,临床医师对其认识越来越深入,与2型糖尿病相比,PTDM在病理生理特征和临床进展上存在着明显差异,需采用不同的治疗策略。及早识别器官移植受者的危险因素,早期诊断和干预对于改善受者的生活质量,延长移植物的存活时间以及降低受者病死率具有重要意义。因此,本文就PTDM的诊断、发生情况及危险因素做一综述,以期为临床医师早期识别并干预PTDM提供参考。

     

  • [1] DE LA FUENTE-MANCERA JC, FORADO-BENTAR I, FARRERO M. Management of long-term cardiovascular risk factors post organ transplant[J]. Curr Opin Organ Transplant, 2022, 27(1): 29-35. DOI: 10.1097/MOT.0000000000000950.
    [2] SHARIF A. Prevention of post-transplantation diabetes: small steps, big opportunities[J]. J Am Soc Nephrol, 2021, 32(8): 1833-1834. DOI: 10.1681/ASN.2021060777.
    [3] WANG Q, WU J, WANG X, et al. Risk factors of new-onset diabetes after renal transplantation and prognostic analysis[J]. Altern Ther Health Med, 2023, 29(2): 230-235.
    [4] 中国康复医学会器官移植康复专业委员会. 成人实体器官移植后糖尿病管理专家共识[J]. 器官移植, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.

    Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation. Expert consensus on diabetes mellitus after solid organ transplantation in adults[J]. Organ Transplant, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.
    [5] HE J, YANG M, QUAN X, et al. Microbial and metabolic features in renal transplant recipients with post-transplantation diabetes mellitus[J]. Int J Urol, 2023, 30(6): 504-513. DOI: 10.1111/iju.15158.
    [6] 陈荣鑫, 赖兴强, 张磊, 等. 肾移植受者发生移植后糖尿病的危险因素分析及预测模型的构建[J]. 器官移植, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.

    CHEN RX, LAI XQ, ZHANG L, et al. Analysis of risk factors and establishment of prediction model for post transplantation diabetes mellitus in renal transplant recipients[J]. Organ Transplant, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.
    [7] WANG L, HUANG J, LI Y, et al. Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients[J]. Endocrine, 2023, 81(1): 58-66. DOI: 10.1007/s12020-023-03374-y.
    [8] SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
    [9] LIN Y, MOK M, HARRISON J, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review[J]. Transplant Rev (Orlando), 2023, 37(1): 100729. DOI: 10.1016/j.trre.2022.100729.
    [10] HARREITER J, RODEN M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 7-17. DOI: 10.1007/s00508-022-02122-y.
    [11] HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
    [12] CHAITOU AR, VALMIKI S, VALMIKI M, et al. New-onset diabetes mellitus (NODM) after liver transplantation (lt): the ultimate non-diabetogenic immunosuppressive therapy[J]. Cureus, 2022, 14(3): e23635. DOI: 10.7759/cureus.23635.
    [13] JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
    [14] PAUCHET A, SCHWOTZER N, LAMINE F, et al. Post-transplantation diabetes in kidney transplant: from the diabetologist point of view[J]. Rev Med Suisse, 2020, 16(697): 1200-1205.
    [15] SHIVASWAMY V, BOERNER B, LARSEN J. Post-Transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
    [16] ZHANG Z, SUN J, GUO M, et al. Progress of new-onset diabetes after liver and kidney transplantation[J]. Front Endocrinol (Lausanne), 2023, 14: 1091843. DOI: 10.3389/fendo.2023.1091843.
    [17] REID L, BAXTER F, FORBES S. Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes[J]. Diabet Med, 2021, 38(7): e14570. DOI: 10.1111/dme.14570.
    [18] KIM NG, SHARMA A, SAAB S. Cardiovascular and metabolic disease in the liver transplant recipient[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101683. DOI: 10.1016/j.bpg.2020.101683.
    [19] DE VRIES DK, LINDEMAN JH, RINGERS J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation[J]. Am J Transplant, 2011, 11(5): 1064-1070. DOI: 10.1111/j.1600-6143.2011.03466.x.
    [20] NAESENS M, LI L, YING L, et al. Expression of complement components differs between kidney allografts from living and deceased donors[J]. J Am Soc Nephrol, 2009, 20(8): 1839-1851. DOI: 10.1681/ASN.2008111145.
    [21] ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
    [22] 中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
    [23] 张岑, 王文妍, 文力. 类固醇相关糖尿病风险防范及诊治[J]. 临床药物治疗杂志, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.

    ZHANG C, WANG WY, WEN L. Risk prevention and treatment of steroid-induced diabetes mellitus[J]. Clin Med J, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.
    [24] WOODLE ES, FIRST MR, PIRSCH J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy[J]. Ann Surg, 2008, 248(4): 564-577. DOI: 10.1097/SLA.0b013e318187d1da.
    [25] WEBSTER AC, WOODROFFE RC, TAYLOR RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data[J]. BMJ, 2005, 331(7520): 810. DOI: 10.1136/bmj.38569.471007.AE.
    [26] NOGUEIRAS-ÁLVAREZ R, MORA-CUESTA VM, CIFRIÁN-MARTÍNEZ JM, et al. Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain[J]. Sci Rep, 2022, 12(1): 21207. DOI: 10.1038/s41598-022-25445-2.
    [27] WANG Z, JIANG Z, LU R, et al. Formulation strategies to provide oxygen-release to contrast local hypoxia for transplanted islets[J]. Eur J Pharm Biopharm, 2023, 187: 130-140. DOI: 10.1016/j.ejpb.2023.04.015.
    [28] VAN LAECKE S, VAN BIESEN W, VERBEKE F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation[J]. Am J Transplant, 2009, 9(9): 2140-2149. DOI: 10.1111/j.1600-6143.2009.02752.x.
    [29] LOMBARDI Y, FRANÇOIS H. Belatacept in kidney transplantation: what are the true benefits? a systematic review[J]. Front Med (Lausanne), 2022, 9: 942665. DOI: 10.3389/fmed.2022.942665.
    [30] ARAKI M, FLECHNER SM, ISMAIL HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs[J]. Transplantation, 2006, 81(3): 335-341. DOI: 10.1097/01.tp.0000195770.31960.18.
    [31] CAMAYA I, DONNELLY S, O'BRIEN B. Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes[J]. J Diabetes, 2022, 14(4): 247-260. DOI: 10.1111/1753-0407.13252.
    [32] OTHMAN N, GHEITH O, AL-OTAIBI T, et al. Effect of structured diabetes education on diabetic angiopathies among kidney transplant recipients with posttransplant diabetes: kuwait experience[J]. Exp Clin Transplant, 2022, 20(Suppl 1): 46-54. DOI: 10.6002/ect.MESOT2021.O19.
    [33] DELOS SANTOS RB, HAGOPIAN JC, CHEN L, et al. Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation-a single-center, randomized, double-blind controlled trial[J]. Transplantation, 2023, 107(5): 1180-1187. DOI: 10.1097/TP.0000000000004373.
    [34] KATHIRVEL M, MALLICK S, SETHI P, et al. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)[J]. HPB (Oxford), 2021, 23(5): 666-674. DOI: 10.1016/j.hpb.2020.09.012.
    [35] 尚梦月, 陈永忠, 保洁, 等. 慢性乙型肝炎合并代谢相关脂肪性肝病的临床及病理特点分析[J]. 中华肝脏病杂志, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113- 20220701-00362.

    SHANG MY, CHEN YZ, BAO J, et al. Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease[J]. Chin J Hepatol, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113-20220701-00362.
    [36] 张绍丽, 曹毛毛, 杨帆, 等. 1990—2019年中国人群肝癌各病因疾病负担变化趋势分析[J]. 中华消化外科杂志, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610- 20221112-00687.

    ZHANG SL, CAO MM, YANG F, et al. Analysis of the change trend of etiological burden of disease of liver cancer in the Chinese population from 1990 to 2019[J]. Chin J Dig Surg, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610-20221112-00687.
    [37] PISANO G, FRACANZANI AL, CACCAMO L, et al. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study[J]. World J Gastroenterol, 2016, 22(40): 8869-8882. DOI: 10.3748/wjg.v22.i40.8869.
    [38] PATIL DT, YERIAN LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation[J]. Liver Transpl, 2012, 18(10): 1147-1153. DOI: 10.1002/lt.23499.
    [39] ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6): 932-940. DOI: 10.5604/01.3001.0010.5285.
  • 加载中
图(1)
计量
  • 文章访问数:  227
  • HTML全文浏览量:  168
  • PDF下载量:  34
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-08-02
  • 网络出版日期:  2023-11-29
  • 刊出日期:  2024-01-11

目录

    /

    返回文章
    返回